Mytide Therapeutics, a Boston, MA-based company transforming peptide manufacturing with predictive analytics and machine learning, raised $7 million in Series A financing.
The round was led by Alloy Therapeutics, a biotechnology ecosystem company, and was joined by Uncommon Denominator and the Mytide founding team.
This financing will allow Mytide to scale its AI-enabled Gen2 platform to support cost-effective, scalable, and decentralized manufacturing for a wide variety of peptide and peptide conjugate applications for therapeutic discovery and personal peptide vaccines (PPV).
As part of the financing, Alloy Therapeutics CEO Errik Anderson will join Mytide’s Board of Directors.
Company: MYTIDE THERAPEUTICS, INC.
Round: Series A
Funding Month: March 2022
Lead Investors: Alloy Therapeutics
Additional Investors: Uncommon Denominator and Mytide founding team
Company Website: https://www.mytide.io/
Software Category: Automated Peptide Manufacturing Platform
About the Company: Mytide Therapeutics is a Boston, MA-based peptide and biopolymer manufacturing and computational biology company focused on eliminating the time-consuming and labor-intensive chemical and screening processes preventing innovative therapeutics’ translation into the clinic. Mytide’s quick-turn manufacturing technology, coupled with AI-enabled predictive analytics, is providing access to a novel peptide space of difficult-to-make natural and non-natural peptide and peptide conjugates discovery and therapeutic manufacturing. The company is focused on the translation of life-saving therapeutics for serious conditions ranging from metabolic conditions to oncology to inflammatory disorders to infectious diseases.